PBYIPuma Biotechnology, Inc.
Is it safe?
Nothing alarming, nothing pristine: comfortable debt (A) and big price swings.
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -99% · now at/near its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can PBYI take a bad year?
Puma Biotechnology, Inc. carries $8.1M of net debt at 0.21× EBITDA: a load its earnings can carry.
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 0.21×
Net debt / EBITDA · −0.99× a year ago · the load is going up
- Interest cover
- 8.65×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 67%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $102M
- Cash and short-term investments
- $94M
- Net debt
- $8.1M
- EBITDA, trailing twelve months
- $38M
- Operating profit, trailing twelve months
- $30M
- Debt / equity
- 0.74×
- Total debt / EBITDA
- 2.67×
- Annualised volatilitytwo years of daily moves
- 67%
- Worst drawdown on file
- −99%
- Below its 52-week high
- 0.00%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.